This makes sense if they are trying to get the paper peer reviewed for DMOAD action, which would require the results from 008. I'd like to know what journal they've submitted to since this would determine how likely the FDA are willing to accept the results of the peer review. I'm surprised PAR do not submit their results to the ACR conference which is the largest and most prestige rheumatology conference in the world.
This makes sense if they are trying to get the paper peer...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.005(2.13%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 23.0¢ | $63.43K | 270.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 213534 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 76890 | 2 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |